Amgen Inc. Reports 7% YOY Revenue Increase in Q2 2023 Financials
US-based biotechnology company Amgen Inc., (NASDAQ: AMGN) has released its financial results for the second...
NASDAQ: AMGN
Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project
This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...
Luye Pharma’s BA1102 Biosimilar to Xgeva Accepted for CDE Review
China-based Luye Pharma Group (HKG: 2186) has announced that a market approval filing for its...
Amgen Reports Q4 and Full-Year 2022 Financials with Global Sales Growth
US major Amgen (NASDAQ: AMGN) has released its Q4 and full-year 2022 financials. Global sales...
Sino Biopharmaceutical Secures Rights to Biosimilar of Amgen’s Xgeva in China
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary CP Pharmaceutical Qingdao has...
Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China
China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...